Mechanisms of thrombocytopenia induced by interferon therapy for chronic hepatitis B
- PMID: 9085169
- DOI: 10.1007/BF02936369
Mechanisms of thrombocytopenia induced by interferon therapy for chronic hepatitis B
Abstract
To clarify the mechanisms of thrombocytopenia observed in patients with chronic hepatitis B treated with interferon. We studied six patients with chronic active hepatitis B who received intramuscular injections of natural interferon-alpha (3 or 5 million IU/ day) for 4 weeks. Peripheral blood platelet counts, bone marrow findings, and platelet kinetics, determined using 111In-labeled platelets, were analyzed. Platelets decreased significantly 1 week after the beginning of treatment and remained decreased until the completion of treatment. The number of nucleated cells and megakaryocytes in bone marrow decreased in three of five patients studied during treatment. The kinetic study showed platelet survival time to be 8.1 +/- 1.3 days (range, 5.8-10.0). One day after platelet injection, platelets accumulated predominantly in the splenic area in all patients, whereas hepatic accumulation was predominant 7 days after injection in three of the six patients. Thrombocytopenia during interferon treatment arises from the inhibition of stem cell proliferation and differentiation in the bone marrow and from the capture of platelets by the liver.
Similar articles
-
[Anti-platelet antibody and severe thrombocytopenia during interferon-alpha therapy for chronic active hepatitis C].Nihon Rinsho Meneki Gakkai Kaishi. 1996 Apr;19(2):150-6. doi: 10.2177/jsci.19.150. Nihon Rinsho Meneki Gakkai Kaishi. 1996. PMID: 8705692 Review. Japanese.
-
Re: life-threatening severe immune thrombocytopenia after alpha-interferon therapy for chronic hepatitis C infection.Am J Gastroenterol. 1996 Apr;91(4):821-2. Am J Gastroenterol. 1996. PMID: 8677971 No abstract available.
-
[Severe thrombocytopenia during interferon-alpha therapy for chronic active hepatitis C associated with systemic lupus erythematosus].Fukuoka Igaku Zasshi. 1994 Nov;85(11):329-33. Fukuoka Igaku Zasshi. 1994. PMID: 7851835 Japanese.
-
Long-term versus short-term treatment with recombinant interferon alfa-2a in patients with chronic hepatitis B: a prospective, randomized treatment trial.Mayo Clin Proc. 1990 Oct;65(10):1330-5. doi: 10.1016/s0025-6196(12)62144-2. Mayo Clin Proc. 1990. PMID: 2214880 Clinical Trial.
-
[Pathogenesis and alpha-2 interferon treatment of chronic hepatitis B].Rev Med Liege. 1996 Aug;51(8):514-21. Rev Med Liege. 1996. PMID: 8927872 Review. French. No abstract available.
Cited by
-
The pathophysiology of thrombocytopenia in chronic liver disease.Hepat Med. 2016 Apr 15;8:39-50. doi: 10.2147/HMER.S74612. eCollection 2016. Hepat Med. 2016. PMID: 27186144 Free PMC article. Review.
-
Clinical spectrum and currently available treatment of type I interferonopathy Aicardi-Goutières syndrome.World J Pediatr. 2023 Jul;19(7):635-643. doi: 10.1007/s12519-022-00679-2. Epub 2023 Jan 17. World J Pediatr. 2023. PMID: 36650407 Free PMC article. Review.
-
Accumulation of platelets in the liver may be an important contributory factor to thrombocytopenia and liver fibrosis in chronic hepatitis C.J Gastroenterol. 2013 Apr;48(4):526-34. doi: 10.1007/s00535-012-0656-2. Epub 2012 Aug 22. J Gastroenterol. 2013. PMID: 22911171
-
Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C.Dig Dis Sci. 2002 Mar;47(3):562-3. doi: 10.1023/a:1017964002402. Dig Dis Sci. 2002. PMID: 11911342 No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical